
Oncology NEWS International
- Oncology NEWS International Vol 18 No 9
- Volume 18
- Issue 9
CyDex set to launch CDX-353 trial for Rx of multiple myeloma
The FDA has accepted an Investigational New Drug (IND) application from CyDex Pharmaceuticals for a clinical study of Captisol-enabled melphalan HCL (CDX-353).
The FDA has accepted an Investigational New Drug (IND) application from CyDex Pharmaceuticals for a clinical study of Captisol-enabled melphalan HCL (CDX-353). Melphalan (Alkeran) is an FDA-approved low-dose chemotherapy for multiple myeloma marketed by GlaxoSmithKline. A phase II(a) trial that compares the pharmacokinetics and safety of CDX-353 with Alkeran is planned. Alkeran is packaged as two vials that must be combined prior to injection and requires immediate administration. CDX-353 is a one-vial formulation that remains stable at room temperature for an extended period of time, according to CyDex.
Articles in this issue
almost 17 years ago
Industry Watchalmost 17 years ago
Letter to the Editoralmost 17 years ago
Novel chemoRT regimen ups survival in pancreatic caalmost 17 years ago
Low expression of MSH2 protein predicts survival in NSCLCalmost 17 years ago
Prostate cancer pilot program stresses patient-oriented carealmost 17 years ago
CT distinguishes liver cancer mets from lung primaryalmost 17 years ago
Prostate cancer patients seek out mind-body carealmost 17 years ago
Who's Newsalmost 17 years ago
Panitumumab plus FOLFIRI bests FOLFIRI alone as second-line colon ca Rx


























































